Juvidex is a topical formulation of the sugar Mannose-6-Phosphate (M-6-P).
Following reporting of the results of the Phase 2 efficacy trial in skin graft donor sites, Renovo decided to out-license Juvidex. This trial showed that topical Juvidex was well tolerated and that objective measures over the healing period demonstrated that wounds treated with topical Juvidex had an appearance that more closely resembled normal skin compared to placebo.
Specifically, Juvidex accelerated re-epithelialisation, reduced redness, improved radiance/blending and improved the overall skin appearance.
Renovo believes that these topical Juvidex data can support key cosmetic claims e.g. for products post chemical/laser peel, dermabrasion, waxing, sunburn, anti-aging cream, lip salve, aftershave, mother and baby, dry skin.
Following the restructuring of the company, Renovo intends to sell the Juvidex programme to a cosmetic company.